# US 2006/0142258 A1 · Estrogen replacement therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0142258 A1
- Document ID: US20060142258A1
- Status: Published application
- Kind: A1
- Application number: 11/349,712
- Filed: 2006-02-08
- Published: 2006-06-29
- Earliest claimed: 2001-03-16
- Assignees: Wyeth
- Inventors: James Pickar
- Web page: https://patentgrep.com/patent/US20060142258A1

## CPC

- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 5/30: Oestrogens
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/02: for disorders of the vagina
- A61P 15/12: for climacteric disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to methods and pharmaceutical compositions for providing estrogen replacement therapy in penmenopausal, menopausal, and postmenopausal women through the continuous administration of conjugated estrogens.

## Claims

### Claim 1

A method of treating or inhibiting menopausal or postmenopausal disorders in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the conjugated estrogens is synthetic conjugated estrogens, A.

### Claim 6

A method of treating or inhibiting vasomotor symptoms in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the vasomotor symptom is hot flushes.

### Claim 11 (depends on 6)

The method according to claim 6, wherein the conjugated estrogens is synthetic conugated estrogens A.

### Claim 12

A method of inhibiting, or retarding bone demineralization or treating or inhibiting osteoporosis in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 g conjugated estrogens.

### Claim 13 (depends on 12)

The method according to claim 12, wherein conjugated estrogens is conjugated equine estrogens, USP.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 16

A method of treating or inhibiting vaginal or vulvar atrophy; atrophic vaginitis; vaginal dryness; pruritus; dyspareunia; dysuria; frequent urination; urinary incontinence; urinary tract infections in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterrupted over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 20

A method of lowering cholesterol, Lp(a), or LDL levels; inhibiting or treating hypercholesteremia; hyperlipidemia, cardiovascular disease, atherosclerosis; peripheral vascular disease; restenosis, vasospasm; or inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage, in a perimenopausal;
menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 24

A method of treating or inhibiting free radical involvement in the development of cancers, central nervous system disorders, Alzheimer's disease, bone disease, aging, inflammatory disorders, peripheral vascular disease, rheumatoid arthritis, autoimmune diseases, respiratory distress, emphysema, prevention of reperfusion injury, viral hepatitis, chronic active hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, aging effects, adult respiratory distress syndrome, central nervous system trauma and stroke, or injury during reperfusion procedures in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the daily dosage of conjugated equine estrogens, is between about 0.2 mg and about 0.1 mg.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 28

A method of treating or inhibiting dementias, neurodegenerative disorders, and Alzheimer's disease; providing neuroprotection or cognition enhancement in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 30 (depends on 31)

The method according to claim 31, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 32

A pharmaceutical composition for use in treating menopausal or postmenopausal disorders, which comprises dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens, and a pharmaceutical carrier.

### Claim 33 (depends on 32)

The composition according to claim 32, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 34 (depends on 33)

The composition according to claim 33, wherein the dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 35 (depends on 34)

The composition according to claim 34, wherein the dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 36

A pharmaceutical dosage unit which comprises which comprises conjugated estrogens, a dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens and a pharmaceutical carrier.

### Claim 37 (depends on 36)

The dosage unit according to claim 36, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 38 (depends on 37)

The dosage unit according to claim 37, wherein the dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 39 (depends on 38)

The dosage unit according to claim 38, wherein the dosage of conjugated, equine estrogens, USP is about 0.2 mg.

### Claim 40

A method of minimizing or reducing levels of breast pain in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 44

A method of minimizing, spotting or breakthrough bleeding; or achieving amenorrhea in a woman receiving hormone replacement therapy, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg.

### Claim 45 (depends on 44)

The method according to claim 44, wherein the conjugated estrogens is conjugated sequine etrogens, USP.

### Claim 46 (depends on 45)

The method according to claim 45, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.

### Claim 48

A method of increasing bone mineral density in a perimenopausal, menopausal, or postmenopausal woman in need thereof, which comprises orally providing to said woman continuously and uninterruptedly over the treatment period, a daily dosage of between about 0.25 mg and about 0.1 mg conjugated estrogens.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the conjugated estrogens is conjugated equine estrogens, USP.

### Claim 50 (depends on 49)

The method according to claim 49, wherein the daily dosage of conjugated equine estrogens is between about 0.2 mg and about 0.1 mg.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the daily dosage of conjugated equine estrogens, USP is about 0.2 mg.
